EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer’s Disease Continuum

Sylvain Lehmann, Susanna Schraen-Maschke, Jean-Sébastien Vidal, Frédéric Blanc iD, Claire Paquet, Bernadette Allinquant, Stéphanie Bombois iD, Audrey Gabelle, Constance Delaby, Olivier Hanon, BALTAZAR Study Group

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms242417361 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Sylvain Lehmann und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire et Plateforme de Protéomique Clinique, Université de Montpellier, INM INSERM, IRMB CHU de Montpellier, 80 av Fliche, F-34295 Montpellier,…. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The French ministry of Health (Programme Hospitalier de Recherche Clinique), French ministry of Health, Foundation Plan Alzheimer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurofilament light chain (NfL) is a potential diagnostic and prognostic plasma biomarker for numerous neurological diseases including Alzheimer’s disease (AD). In this study, we investigated the relationship between baseline plasma concentration of Nfl and Mild Cognitive Impairment in participants who did and did not have a clinically determined diagnosis of dementia by the end of the three-year study. Additionally, we explored the connection between baseline plasma concentration of NfL and AD dementia patients, considering their demographics, clinical features, and cognitive profiles. A total of 350 participants from the Biomarker of AmyLoid pepTide and AlZheimer’s diseAse Risk (BALTAZAR) multicenter prospective study were investigated: 161 AD dementia participants and 189 MCI participants (of which 141 had amnestic MCI and 48 non-amnestic MCI). Plasma biomarkers were measured at baseline and the progression of clinical and cognitive profiles was followed over the three years of follow-up. Baseline plasma NfL concentration increased across the Alzheimer’s disease continuum with a mean NfL value of 17.1 ng/mL [SD = 6.1] in non-amnestic MCI, 20.7 ng/mL [SD = 12.0] in amnestic MCI, and 23.1 ng/mL [SD = 22.7] in AD dementia patients. Plasma NfL concentration correlated with age, body mass index (BMI), and global cognitive performance and decline, as measured by the Mini-Mental State Examination (MMSE). MMSE scores decreased in parallel with increasing plasma NfL concentration, independently of age and BMI. However, NfL concentration did not predict MCI participants’ conversion to dementia within three years. Discussion: Baseline plasma NfL concentration is associated with cognitive status along the AD continuum, suggesting its usefulness as a potential informative biomarker for cognitive decline follow-up in patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCognitive DysfunctionHumansProspective StudiesIntermediate FilamentsNeurofilament ProteinsBiomarkersAmyloid beta-PeptidesDisease Progressiontau Proteins

Stichwörter der Autor:innen

Alzheimer’s diseasebloodcognitive declineneurofilament light chain

Substanzen

Neurofilament ProteinsBiomarkersAmyloid beta-Peptidestau Proteins

Autor:innen und Institutionen

  • Laboratoire et Plateforme de Protéomique Clinique, Université de Montpellier, INM INSERM, IRMB CHU de Montpellier, 80 av Fliche, F-34295 Montpellier, France.
  • Univ. Lille, Inserm, CHU Lille, UMR-S-U1172, LiCEND, Lille Neuroscience & Cognition, LabEx DISTALZ, F-59000 Lille, France.
  • Université Paris Cité, INSERM U1144, GHU APHP Centre, Hopital Broca, Memory Resource and Research Centre de Paris-Broca-Ile de France, F-75013 Paris, France.
  • Université de Strasbourg, Hôpitaux Universitaires de Strasbourg, Memory Resource and Research, French National Centre for Scientific Research (CNRS), ICube Laboratory UMR7357 and Fédération de Médecine Translationnelle…
  • Université Paris Cité, INSERM U1144, GHU APHP Nord Lariboisière Fernand Widal, Centre de Neurologie Cognitive, F-75010 Paris, France.
  • Université Paris Cité, Institute of Psychiatry and Neurosciences, Inserm, UMR-S 1266, F-75014 Paris, France.

ORCID-Profile: Frédéric Blanc, Stéphanie Bombois

Förderung

  • The French ministry of Health (Programme Hospitalier de Recherche Clinique)
  • French ministry of Health
  • Foundation Plan Alzheimer
  • Fondation pour la Recherche Médicale (FRM)
  • The Gerontopôle d’Ile de France (GERONDIF)

Zitieren

APA

Lehmann, S., Schraen-Maschke, S., Vidal, J. S., Blanc, F., Paquet, C., Allinquant, B., Bombois, S., Gabelle, A., Delaby, C., Hanon, O., & BALTAZAR Study Group (2023). Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer’s Disease Continuum. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242417361

Vancouver

Lehmann S, Schraen-Maschke S, Vidal JS, Blanc F, Paquet C, Allinquant B, et al. Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer’s Disease Continuum. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242417361

BibTeX
@article{Lehmann2023,
  author = {Lehmann, Sylvain and Schraen-Maschke, Susanna and Vidal, Jean-Sébastien and Blanc, Frédéric and Paquet, Claire and Allinquant, Bernadette and Bombois, Stéphanie and Gabelle, Audrey and Delaby, Constance and Hanon, Olivier and BALTAZAR Study Group, BALTAZAR Study Group},
  title = {Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer’s Disease Continuum},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms242417361}
}
Kostenlos starten →